RAD51 protein is a predictor of chemosensitivity and survival prognosis in patients with advanced high-grade serous ovarian cancer undergoing neoadjuvant chemotherapy
RAD51 protein expression is closely related to the sensitivity of neoadjuvant chemotherapy in advanced high-grade serous ovarian cancer. RAD51 protein expression offers a valuable tool for predicting chemotherapy sensitivity, platinum resistance recurrence, and survival outcomes in patients with advanced epithelial ovarian cancer.
Authors
- Yufang Xia
- Huiyang Qi
- Yunqing Chen (ORCID: https://orcid.org/0000-0002-4100-7220)
- Hui Liu (ORCID: https://orcid.org/0000-0003-0481-2607)
- Shujun Ji
- Huixiang Ji
- Yanhui Lou
Institutions
- Qingdao University (CN)
- People’s Hospital of Rizhao (CN)
- Linyi People's Hospital (CN)
- Affiliated Hospital of Qingdao University (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-10-22
- DOI
- https://doi.org/10.3389/fonc.2025.1548889
- Citations
- 1
- Primary Topic
- Ovarian cancer diagnosis and treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.70